Immunotherapy of melanoma

被引：43

作者：

Parmiani, G ^{[1
]}

Castelli, C ^{[1
]}

Rivoltini, L ^{[1
]}

Casati, C ^{[1
]}

Tully, GA ^{[1
]}

Novellino, L ^{[1
]}

Patuzzo, A ^{[1
]}

Tosi, D ^{[1
]}

Anichini, A ^{[1
]}

Santinami, M ^{[1
]}

机构：

[1] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy

来源：

SEMINARS IN CANCER BIOLOGY | 2003年 / 13卷 / 06期

关键词：

melanoma; antigens; vaccination; adoptive immunotherapy; TUMOR-INFILTRATING LYMPHOCYTES; COLONY-STIMULATING FACTOR; CD8(+) T-CELLS; PHASE-I TRIAL; HEAT-SHOCK-PROTEIN-70 PEPTIDE COMPLEXES; INCOMPLETE FREUNDS-ADJUVANT; BLOOD MONONUCLEAR-CELLS; PULSED DENDRITIC CELLS; HEAT-SHOCK PROTEINS; METASTATIC MELANOMA;

D O I：

10.1016/j.semcancer.2003.09.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：391 / 400

页数：10

共 79 条

[41] Mortarini R, 2003, CANCER RES, V63, P2535
[42] Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
Nair, SK
Boczkowski, D
Morse, M
Cumming, RI
Lyerly, HK
Gilboa, E
[J]. NATURE BIOTECHNOLOGY, 1998, 16 (04) : 364 - 369
[43] Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells
Noessner, E
Gastpar, R
Milani, V
Brandl, A
Hutzler, PJS
Kuppner, MC
Roos, M
Kremmer, E
Asea, A
Calderwood, SK
Issels, RD
[J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (10) : 5424 - 5432
[44] Identification of a mutated receptor-like protein tyrosine phosphatase κ as a novel, class IIHLA-restricted melanoma antigen
Novellino, L
Renkvist, N
Rini, F
Mazzocchi, A
Rivoltini, L
Greco, A
Deho, P
Squarcina, P
Robbins, PF
Parmiani, G
Castelli, C
[J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (12) : 6363 - 6370
[45] Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells
Oelke, M
Maus, MV
Didiano, D
June, CH
Mackensen, A
Schneck, JP
[J]. NATURE MEDICINE, 2003, 9 (05) : 619 - 624
[46] Immunological gene therapy with ex vivo gene-modified tumor cells:: A critique and a reappraisal
Parmiani, G
Rodolfo, M
Melani, C
[J]. HUMAN GENE THERAPY, 2000, 11 (09) : 1269 - 1275
[47] Parmiani G, 1997, Adv Pharmacol, V40, P259, DOI 10.1016/S1054-3589(08)60142-8
[48] Cancer immunotherapy with peptide-based vaccines: What have we achieved? - Where are we going?
Parmiani, G
Castelli, C
Dalerba, P
Mortarini, R
Rivoltini, L
Marincola, FM
Anichini, A
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11): : 805 - 818
[49] PARMIANI G, 2002, MELANOMA TECHNIQUES, P203
[50] Parmiani Giorgio, 2002, Cancer Immun, V2, P6

← 1 2 3 4 5 6 7 8 →